Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402530 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I
A Phase 2 study, sponsored by Grünenthal.
- Completed
- Registry status
- Phase 2
- Development phase
- 459
- Enrollment target
NCT02402530 is a Phase 2 study that has completed, run by Grünenthal. The registered enrollment target is 459 participants.
The verdict
NCT02402530, a Phase 2 study, has completed, sponsored by Grünenthal.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 459 participants
- Enrollment target
Study Summary
This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the treatment of pain associated with complex regional pain syndrome type I (CRPS-I). The trial is divided into 3 periods: a 60-day enrollment period, a 12-week trial period, and an extended follow-up period with visits at Month 6, Month 9, and Month 12. The extended follow-up period will be terminated for all participants after the last participant enrolled completes their Month 6 visit (Visit 9). The double-blind will be maintained throughout the 12-week trial period and extended follow-up period.
Interventions
- DRUG Placebo
- DRUG Neridronic acid 62.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02402530
The ClinicalTrials.gov registry entry for NCT02402530 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grünenthal, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02402530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02402530 about?
NCT02402530 is a clinical study titled "Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I". This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the treatment of pain associated with complex regional pain syndrome type I (CRPS-I). The trial is divided into 3 periods: a 60-day enrollment period, a 12-week trial period, and an extended follow-up period wi...
What is the current status of trial NCT02402530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 459 participants. The study started on 2015-04. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02402530?
The interventions under investigation include: Placebo (DRUG), Neridronic acid 62.5 mg (DRUG).
Who is sponsoring clinical trial NCT02402530?
This trial is sponsored by Grünenthal, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.